Screening in Myocardial Perfusion Patients

Screening for Breast Cancer in Patients Undergoing Myocardial Perfusion Imaging

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00943241

Enrollment

322

Registered

2009-07-22

Start date

2008-07-31

Completion date

2010-06-30

Last updated

2013-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Breast, Breast Cancer, MBI, Molecular Breast Imaging, Molecular Imaging

Brief summary

To expand the understanding of the uptake and distribution of Tc-99m sestamibi in the breast in a normal female population undergoing myocardial perfusion imaging using Molecular Breast Imaging (MBI).

Detailed description

You are being asked to take part in this research study because you have been scheduled to have a scan of your heart. The radioactive dye used to image your heart is also taken up by many types of breast cancer. The investigators have developed a new method for detecting breast cancer, called Molecular Breast Imaging that uses this dye. The purpose of this study is to see how well this new method works in normal subjects with no known breast cancer and to see if we can detect breast cancer at an earlier stage than mammography. As you read this form describing the study, ask any questions you have. Take your time to decide. Feel free to discuss the study with your family, friends, and healthcare provider before you decide. You may stop participating at any time during the study. You may decide not to participate. If so, none of your current benefits or normal health care will be affected in any way. When you feel comfortable that all your questions have been answered, and you wish to take part in this study, sign this form in order to begin your participation. Your signature means you have been told about the study and what the risks are. Your signature on this form also means that you want to take part in this study.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

* They have had a mammogram at Mayo Clinic Rochester within the last 12 months * Undergoing myocardial perfusion imaging

Exclusion criteria

* They are unable to understand and sign the consent form * They are physically unable to sit upright and still for 20 minutes * They have undergone breast surgery or breast biopsy within the last 12 months. * They have had trauma to the breast tissue or undergone radiation treatment to the breast within the last 12 months.

Design outcomes

Primary

Measure	Time frame
Biopsy-proven breast cancer	12 months

Countries

United States

Outcome results